Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

by B2i | Mar 13, 2025 | Press Releases

GAITHERSBURG, Md., March 13, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

by B2i | Mar 12, 2025 | Press Releases

GAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

by B2i | Mar 12, 2025 | Press Releases

Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the...

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

by B2i | Feb 26, 2025 | Press Releases

GAITHERSBURG, Md., Feb. 26, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer...

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

by B2i | Jan 21, 2025 | Press Releases

GAITHERSBURG, Md., Jan. 21, 2025 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...